As the dose and frequency of administration were increased, the animals treated with LH saw improved effects of the drugs on cancer symptoms, as follows: low dose (30.8%), medium dose (56.4%), high dose (92.4%), and the twice-a-week high dose (90.6%). The gene discussed is PLOD1; the disease is cancer.